黄斑変性症（AMD）およびその他の網膜疾患治療薬市場レポート：2023-2033

Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Report 2023-2033

レポート詳細黄斑変性症（AMD）およびその他の網膜疾患治療薬市場レポート 2023-2033 :本レポートは、新たな収益の柱を目指す大手企業にとって、業界とその根底にある力学をより深く理解する上で貴... もっと見る

出版社	出版年月	電子版価格	ページ数	言語
Visiongain ヴィジョンゲイン社	2023年10月10日	GBP4,500 部署ライセンスライセンス・価格情報注文方法はこちら	284	英語

※上記価格は部署ライセンス（Departmental licence）価格です。
その他の価格についてはデータリソースまでお問合せください。
日本語のページは自動翻訳を利用し作成しています。
実際のレポートは英文のみでご納品いたします。

目次
図表リスト

サマリー

レポート詳細

黄斑変性症（AMD）およびその他の網膜疾患治療薬市場レポート 2023-2033:本レポートは、新たな収益の柱を目指す大手企業にとって、業界とその根底にある力学をより深く理解する上で貴重なものとなろう。異業種への進出や、新たな地域での既存事業の拡大を希望する企業にとっても有用であろう。

網膜疾患の発生率の上昇と老年人口の増加が産業の成長を牽引
黄斑変性症（AMD）およびその他の網膜疾患市場の成長は、さまざまな重要な要因によって大きく牽引されている。主な要因は、網膜疾患、特に黄斑変性症の発生が増加していることである。これらの疾患の有病率は世界的に上昇傾向にあり、高齢化、不健康なライフスタイル、喫煙や長時間のスクリーン使用といったリスク要素への曝露の増加といった要因が原因となっている。高齢者の視力低下の主な原因である黄斑変性症は、眼科分野で注目されており、その結果、研究開発や革新的な治療法への投資が増加している。

さらに、高齢者人口の増加が市場の成長に大きく寄与している。高齢化に伴い、AMDなどの網膜疾患を発症する可能性が高まる。世界的に高齢者の割合が増加しているため、こうした状態を管理し、視力を維持するための効果的な治療に対する需要が高まっている。このような人口動態の変化は、高度な治療薬と包括的な管理戦略の必要性を際立たせ、AMDやその他の網膜疾患を対象とする医薬品・治療薬市場を牽引している。

まとめると、網膜疾患の発生件数の増加と高齢者人口の拡大が相まって、黄斑変性症（AMD）およびその他の網膜疾患市場の進歩に対する大きな需要が浮き彫りになっている。このことは、高齢化人口の進化する医療ニーズに対応するために、継続的な研究、技術革新、利用しやすい治療法の重要性を浮き彫りにしている。

AMDに関する認識不足が市場成長の課題になりそう
黄斑変性症（AMD）およびその他の網膜疾患の治療市場は、AMDに関する認識不足という大きな課題によって大きな影響を受けている。この苦境は、視力障害や視力喪失をもたらす進行性の目の病気であるAMDについて、一般市民と医療専門家の両方が限られた理解と知識しか持っていないことに起因している。この問題の中心は、多くの人々、特に弱い立場の人々が、AMDに関連する危険因子、症状、潜在的な結果について認識不足であるという事実である。

このような認識不足は、早期診断と適時の介入に顕著な障害をもたらす。なぜなら、罹患者は進行段階に達するまでAMDの指標を特定できず、治療選択肢の有効性を低下させる可能性があるからである。さらに、医療従事者は、定期的なスクリーニングが行われていないことや、AMDに関する社会教育が不十分であることから、初期段階でAMDを発見することが困難である。

市場調査レポートを購入する前にすべき質問とは？
- 黄斑変性症（AMD）およびその他の網膜疾患治療薬市場はどのように進化しているのか？
- 黄斑変性症（AMD）およびその他の網膜疾患治療薬市場の促進要因と抑制要因は何か？
- 黄斑変性症（AMD）およびその他の網膜疾患治療薬市場の各セグメントは予測期間中にどのように成長し、2033年にこれらのサブマーケットがどれくらいの収益を占めるようになるのか？
- 2023年から2033年にかけて、黄斑変性症（AMD）およびその他の網膜疾患治療薬市場の各サブマーケットの市場シェアはどのように推移するのか？
- 2023年から2033年にかけて市場全体の主な牽引役は何か？
- 主要な黄斑変性症（AMD）およびその他の網膜疾患治療薬市場はマクロ経済の動きに概ね追随するのか、それとも個々の国市場が他を凌駕するのか？
- 2033年までに各国市場のシェアはどのように変化し、2033年に市場をリードするのはどの地域か？
- 主要プレーヤーは誰で、予測期間中の見通しは？
- 2023年から2033年の間に、業界はどのように発展していくのか？黄斑変性症（AMD）およびその他の網膜疾患治療薬のプロジェクトが現在および今後10年間に実施される意味は？
- 黄斑変性症（AMD）およびその他の網膜疾患治療薬市場をさらに拡大するために、製品化の必要性は高まっていますか？
- 黄斑変性症（AMD）およびその他の網膜疾患治療薬市場はどこに向かっており、どのようにすれば市場の最前線に立てるのか？
- 新製品や新サービスへの最適な投資方法とは？
- 企業を新たな成長軌道に乗せ、C-suiteに移行させるための重要な展望とは？

このことが黄斑変性症（AMD）およびその他の網膜疾患治療薬市場に現在、そして今後10年間でどのような影響を与えるかを知る必要がある：
- 284ページにわたる本レポートでは、115の表、151の図表を掲載しています。
- 本レポートでは、業界における主要な有利分野を取り上げているため、今すぐターゲットを絞ることができます。
- 世界、地域、国の売上と成長に関する詳細な分析が含まれています。
- 競合他社が成功した主なトレンド、変化、収益予測をハイライトしています。

本レポートは、黄斑変性症（AMD）およびその他の網膜疾患治療薬市場が今後10年間でどのように発展していくのか、またCOVID-19の景気後退と好転の変動に合わせてどのように発展していくのかをお伝えします。この市場は、過去10年間のどの時点よりも今が重要である。

2033年までの予測やその他の分析から、商業的な展望が明らかになる
- 2033年までの収益予測に加え、直近の業績、成長率、市場シェアもご覧いただけます。
- ビジネスの展望と展開に関する独自の分析をご覧いただけます。
- 定性的分析（市場ダイナミクス、促進要因、機会、阻害要因、課題を含む）、コスト構造、医薬品開発価格上昇の影響、最近の動向をご覧いただけます。

本レポートには、COVID-19が業界と貴社にどのような影響を与えるかについてのデータ分析と貴重な洞察が含まれています。COVID-19の4つの回収パターンとその影響、すなわち「V」、「L」、「W」、「U」について本レポートでは論じている。

適応疾患
・AMD
- 湿性AMD
- ドライAMD
・糖尿病黄斑浮腫
・糖尿病網膜症
・網膜静脈閉塞症
・その他

投与経路
- 非経口
- 外用薬

ブランド
- ルーセンティス
- アイリーア
- アバスチン
- ベオーブ
- バビスモ
- オズールデックス
- その他

流通チャネル
- 病院薬局
- 小売薬局
- Eコマース薬局

世界市場全体と各分野の収益予測に加え、5つの地域と24の主要国市場の収益予測も掲載している：

北米
- アメリカ
- カナダ

欧州
- ドイツ
- 英国
- フランス
- イタリア
- スペイン
- オランダ
- スイス
- その他の欧州

アジア太平洋
- 中国
- 日本
- インド
- オーストラリア
- 韓国
- 東南アジア
- その他のアジア太平洋地域

ラテンアメリカ
- ブラジル
- メキシコ
- アルゼンチン
- その他のラテンアメリカ

MEA
- GCC諸国
- 南アフリカ
- その他のMEA

また、黄斑変性症（AMD）およびその他の網膜疾患治療薬市場の2023年から2033年にかけての主要企業のプロファイルと、これらの企業の事業のこのセグメントに焦点を当てています。

主要企業と市場成長の可能性
・ AbbVie Inc.
・ Alimera Sciences
・ Apellis Pharmaceuticals
・ Bausch ＆ Lomb Incorporated
・ Bayer AG
・ Breye Therapeutics ApS
・ EyeBio
・ F. Hoffmann-La Roche Ltd.
・ Johnson ＆ Johnson Services, Inc.
・ Novartis AG
・ Pfizer Inc.
・ Regeneron Pharmaceuticals Inc.
・ Santen Pharmaceutical Co., Ltd.
・ SpliceBio
・ Teva Pharmaceutical Industries Ltd.

黄斑変性症（AMD）およびその他の網膜疾患治療薬市場の2023～2033年の世界全体の売上高は、金額ベースで2023年に150億米ドルを超えると弊社は算出した。2033年まで力強い収益成長を予測。当研究所では、最も大きな可能性を秘めた企業を特定しています。彼らの能力、進歩、商業的展望を発見し、一歩先を行くお手伝いをします。

黄斑変性症（AMD）とその他の網膜疾患治療薬市場、2023-2033年レポートはどのようにお役に立つでしょうか？
要約すると、280ページを超えるこのレポートは、以下の知識を提供する：

- 黄斑変性症（AMD）およびその他の網膜疾患治療薬市場の2023年～2033年までの収益予測世界および地域レベルでの疾患適応症、投与経路、流通チャネル、ブランドごとの予測を掲載 - 業界の展望を発見し、投資と収益に最も有利な場所を見つけます。

- 5つの地域と24の主要国市場の2033年までの収益予測 - 北米、欧州、アジア太平洋、中南米、MEAの黄斑変性症（AMD）およびその他の網膜疾患治療薬市場の2023年から2033年までの予測をご覧ください。また、米国、カナダ、メキシコ、ブラジル、ドイツ、フランス、英国、イタリア、中国、インド、日本、オーストラリアなどの著名経済圏の市場も予測しています。

- 既存企業および市場参入を目指す企業の展望 - 黄斑変性症（AMD）およびその他の網膜疾患治療薬市場に関わる主要企業15社の企業プロファイルを含む、2023年から2033年までの市場。

独自の予測による定量的・定性的分析をご覧ください。私たちのレポートだけに含まれる情報を入手し、貴重なビジネスインテリジェンスで情報を得ることができます。

他にはない情報
私たちの新しいレポートがあれば、知識に遅れをとったり、チャンスを逃したりする可能性が低くなります。弊社のレポートが貴社の調査、分析、意思決定にどのように役立つかをご覧ください。Visiongainの調査は、黄斑変性症（AMD）およびその他の網膜疾患治療薬市場、2023年から2033年、市場をリードする企業の商業的分析を必要とするすべての人のためのものです。データ、動向、予測をご覧いただけます。

ページTOPに戻る

1 レポート概要
1.1 研究の目的
1.2 黄斑変性症（AMD）およびその他の網膜疾患治療薬市場の紹介
1.3 本レポートの内容
1.4 本レポートを読むべき理由
1.5 本分析レポートが回答する主な質問
1.6 本レポートは誰のためのものか？
1.7 方法論
1.7.1 市場の定義
1.7.2 市場評価・予測手法
1.7.3 データの検証
1.7.3.1 一次調査
1.7.3.2 セカンダリーリサーチ
1.8 よくある質問（FAQ）
1.9 Visiongainの関連レポート
1.10 Visiongainについて

2 エグゼクティブ・サマリー

3 市場概要
3.1 主要な調査結果
3.2 市場ダイナミクス
3.2.1 市場促進要因
3.2.1.1 網膜疾患の発生率の上昇
3.2.1.2 老年人口の増加
3.2.1.3 各国政府による医療費の増加
3.2.2 市場抑制要因
3.2.2.1 AMDに関する認識不足
3.2.2.2 薬の副作用
3.2.2.3 黄斑変性やその他の網膜疾患に関連する高コスト
3.2.3 市場機会
3.2.3.1 網膜疾患の最先端治療に対する需要の高まりが市場を後押しする
3.2.3.2 ドライ型AMD治療の未開拓機会
3.2.3.3 治療のための新技術採用の増加
3.3 COVID-19の影響分析
3.4 ポーターのファイブフォース分析
3.4.1 サプライヤーの交渉力
3.4.2 買い手の交渉力
3.4.3 競争相手のライバル関係
3.4.4 代替品による脅威
3.4.5 新規参入企業の脅威
3.5 PEST分析
3.5.1 政治的要因
3.5.2 経済
3.5.3 社会
3.5.4 技術的

4 黄斑変性（AMD）およびその他の網膜疾患治療薬市場分析：適応疾患別
4.1 主な調査結果
4.2 適応疾患別セグメント市場魅力度指数
4.3 黄斑変性（AMD）およびその他の網膜疾患治療薬の疾患適応別市場規模推定と予測
4.4 AMD
4.4.1 2023〜2033年の地域別市場規模（US$ Billion）
4.4.2 地域別市場シェア、2023年・2033年(%)
4.4.3 黄斑変性症（AMD）およびその他の網膜疾患治療薬市場
4.5 糖尿病黄斑浮腫
4.5.1 2023〜2033年の地域別市場規模（US$ Billion）
4.5.2 地域別市場シェア、2023年・2033年(%)
4.6 糖尿病網膜症
4.6.1 2023〜2033年の地域別市場規模（US$ Billion）
4.6.2 地域別市場シェア、2023年・2033年(%)
4.7 網膜静脈閉塞症
4.7.1 2023〜2033年の地域別市場規模（US$ Billion）
4.7.2 地域別市場シェア、2023年・2033年(%)
4.8 その他
4.8.1 2023〜2033年の地域別市場規模（US$ Billion）
4.8.2 地域別市場シェア、2023年・2033年(%)

5 黄斑変性（AMD）およびその他の網膜疾患治療薬市場分析：投与経路別
5.1 主要調査結果
5.2 投与経路セグメント市場魅力度指数
5.3 黄斑変性症（AMD）およびその他の網膜疾患治療薬の投与経路別市場規模推定と予測
5.4 硝子体内投与ルート
5.4.1 2023〜2033年の地域別市場規模（US$ Billion）
5.4.2 地域別市場シェア、2023年・2033年(%)
5.5 静脈注射ルート
5.5.1 2023〜2033年の地域別市場規模（US$ Billion）
5.5.2 地域別市場シェア、2023年・2033年(%)

6 黄斑変性（AMD）およびその他の網膜疾患治療薬市場分析：流通チャネル別
6.1 主要調査結果
6.2 流通チャネルセグメント市場魅力度指数
6.3 黄斑変性症（AMD）およびその他の網膜疾患治療薬の流通チャネル別市場規模推定と予測
6.4 病院薬局
6.4.1 2023〜2033年の地域別市場規模（US$ Billion）
6.4.2 地域別市場シェア、2023年・2033年(%)
6.5 小売薬局
6.5.1 2023〜2033年の地域別市場規模（US$ Billion）
6.5.2 地域別市場シェア、2023年・2033年(%)
6.6 電子商取引薬局
6.6.1 2023〜2033年の地域別市場規模（US$ Billion）
6.6.2 地域別市場シェア、2023年・2033年(%)

7 黄斑変性（AMD）およびその他の網膜疾患治療薬市場分析：ブランド別
7.1 主要な調査結果
7.2 黄斑変性症（AMD）およびその他の網膜疾患治療薬のブランド別市場規模推定と予測

8 黄斑変性症（AMD）およびその他の網膜疾患治療薬市場分析：地域別
8.1 主要な調査結果
8.3 地域別市場規模の推定と予測

9 北米の黄斑変性症（AMD）およびその他の網膜疾患治療薬の市場分析
9.1 主要な調査結果
9.2 北米の黄斑変性症（AMD）およびその他の網膜疾患治療薬市場魅力度指数
9.3 北米の黄斑変性症（AMD）およびその他の網膜疾患治療薬国別市場、2023年、2028年、2033年（US$ Billion）
9.4 北米の黄斑変性症（AMD）およびその他の網膜疾患治療薬市場規模推定と予測：国別
9.5 北米の黄斑変性症（AMD）およびその他の網膜疾患治療薬市場規模推定と予測：適応疾患別
9.5.1 北米の黄斑変性症（AMD）およびその他網膜疾患治療薬市場規模推定と予測：適応疾患別
9.6 北米の黄斑変性症（AMD）およびその他の網膜疾患治療薬市場規模推定と予測：投与経路別
9.7 北米の黄斑変性症（AMD）およびその他の網膜疾患治療薬市場規模推定と予測：流通経路別
9.8 米国の黄斑変性症（AMD）およびその他の網膜疾患治療薬市場分析
9.9 カナダの黄斑変性症（AMD）およびその他の網膜疾患治療薬市場分析

10 欧州の黄斑変性症（AMD）およびその他の網膜疾患治療薬市場分析
10.1 主要な調査結果
10.2 欧州の黄斑変性症（AMD）およびその他の網膜疾患治療薬市場魅力度指数
10.3 欧州の黄斑変性症（AMD）およびその他の網膜疾患治療薬国別市場、2023年、2028年、2033年（US$ Billion）
10.4 欧州の黄斑変性症（AMD）およびその他の網膜疾患治療薬市場規模推定と予測：国別
10.5 欧州の黄斑変性症（AMD）およびその他の網膜疾患治療薬市場規模推定と予測：適応疾患別
10.5.1 欧州の黄斑変性症（AMD）およびその他の網膜疾患治療薬市場規模推定と予測：適応疾患別
10.6 欧州の黄斑変性症（AMD）およびその他の網膜疾患治療薬の市場規模推定と予測：投与経路別
10.7 欧州の黄斑変性症（AMD）およびその他の網膜疾患治療薬の市場規模推定と予測：流通経路別
10.8 ドイツの黄斑変性症（AMD）およびその他の網膜疾患治療薬の市場分析
10.9 フランスの黄斑変性症（AMD）およびその他の網膜疾患治療薬の市場分析
10.10 イギリスの黄斑変性症（AMD）およびその他の網膜疾患治療薬の市場分析
10.11 イタリアの黄斑変性症（AMD）およびその他の網膜疾患治療薬の市場分析
10.12 スペインの黄斑変性症（AMD）およびその他の網膜疾患治療薬の市場分析
10.13 オランダの黄斑変性症（AMD）およびその他の網膜疾患治療薬の市場分析
10.14 スイスの黄斑変性症（AMD）およびその他の網膜疾患治療薬の市場分析
10.15 その他の欧州の黄斑変性症（AMD）およびその他の網膜疾患治療薬の市場分析

11 アジア太平洋地域の黄斑変性症（AMD）およびその他の網膜疾患治療薬市場分析
11.1 主要な調査結果
11.2 アジア太平洋地域の黄斑変性症（AMD）およびその他の網膜疾患治療薬市場魅力度指数
11.3 アジア太平洋地域の黄斑変性症（AMD）およびその他の網膜疾患治療薬の国別市場、2023年、2028年、2033年（US$ Billion）
11.4 アジア太平洋地域の黄斑変性症（AMD）およびその他の網膜疾患治療薬市場規模推定と予測：国別
11.5 アジア太平洋地域の黄斑変性症（AMD）およびその他の網膜疾患治療薬市場規模推定と予測：適応疾患別
11.5.1 アジア太平洋地域の黄斑変性症（AMD）およびその他の網膜疾患治療薬市場規模推定と予測：適応疾患別
11.6 アジア太平洋地域の黄斑変性症（AMD）およびその他の網膜疾患治療薬市場規模推定と予測：投与経路別
11.7 アジア太平洋地域の黄斑変性症（AMD）およびその他の網膜疾患治療薬市場規模推定と予測：流通経路別
11.8 日本の黄斑変性症（AMD）およびその他の網膜疾患治療薬市場分析
11.9 中国の黄斑変性症（AMD）およびその他の網膜疾患治療薬市場分析
11.10 インド黄斑変性症（AMD）およびその他の網膜疾患治療薬市場分析
11.11 オーストラリアの黄斑変性症（AMD）およびその他の網膜疾患治療薬市場分析
11.12 韓国の黄斑変性症（AMD）およびその他の網膜疾患治療薬市場分析
11.13 東南アジアの黄斑変性症（AMD）およびその他の網膜疾患治療薬市場分析
11.14 その他のアジア太平洋地域の黄斑変性症（AMD）およびその他の網膜疾患治療薬市場分析

12 ラテンアメリカの黄斑変性症（AMD）とその他の網膜疾患治療薬市場分析
12.1 主要な調査結果
12.2 ラテンアメリカの黄斑変性症（AMD）およびその他の網膜疾患治療薬市場魅力度指数
12.3 ラテンアメリカの黄斑変性症（AMD）およびその他の網膜疾患治療薬国別市場、2023年、2028年＆2033年（US$ Billion）
12.4 ラテンアメリカの黄斑変性症（AMD）およびその他の網膜疾患治療薬市場規模推定と予測：国別
12.5 ラテンアメリカの黄斑変性症（AMD）およびその他の網膜疾患治療薬市場規模推定と予測：適応疾患別
12.5.1 ラテンアメリカの黄斑変性症（AMD）およびその他の網膜疾患治療薬市場規模推定と予測：適応疾患別
12.6 ラテンアメリカの黄斑変性症（AMD）およびその他の網膜疾患治療薬市場規模推定と予測：投与経路別
12.7 ラテンアメリカの黄斑変性症（AMD）およびその他の網膜疾患治療薬市場規模推定と予測：流通経路別
12.8 ブラジルの黄斑変性症（AMD）およびその他の網膜疾患治療薬市場分析
12.9 メキシコの黄斑変性症（AMD）およびその他の網膜疾患治療薬市場分析
12.10 アルゼンチン黄斑変性症（AMD）およびその他の網膜疾患治療薬市場分析
12.11 その他のラテンアメリカの黄斑変性症（AMD）およびその他の網膜疾患治療薬市場分析

13 MEAの黄斑変性症（AMD）とその他の網膜疾患治療薬の市場分析
13.1 主要な調査結果
13.2 MEAの黄斑変性症（AMD）およびその他の網膜疾患治療薬市場魅力度指数
13.3 MEAの黄斑変性症（AMD）およびその他の網膜疾患治療薬国別市場、2023年、2028年＆2033年（US$ Billion）
13.4 MEAの黄斑変性症（AMD）およびその他の網膜疾患治療薬市場規模推定と予測：国別
13.5 MEAの黄斑変性症（AMD）およびその他の網膜疾患治療薬市場規模推定と予測：適応疾患別
13.5.1 MEAの黄斑変性症（AMD）およびその他の網膜疾患治療薬市場規模推定と予測：適応疾患別
13.6 MEAの黄斑変性症（AMD）およびその他の網膜疾患治療薬市場規模推定と予測：投与経路別
13.7 MEAの黄斑変性症（AMD）およびその他の網膜疾患治療薬市場規模推定と予測：流通経路別
13.8 GCCの黄斑変性（AMD）およびその他の網膜疾患治療薬市場分析
13.9 南アフリカの黄斑変性症（AMD）およびその他の網膜疾患治療薬市場分析
13.10 その他のMEAの黄斑変性症（AMD）およびその他の網膜疾患治療薬市場分析

14 主要企業のプロファイル
14.1 競争環境、2023年
14.2 戦略的展望
14.3 Novartis AG
14.3.1 会社概要
14.3.2 会社概要
14.3.3 財務分析
14.3.3.1 純収入、2018-2022年
14.3.3.2 地域市場シェア、2022年
14.3.3.3 研究開発費、2018年～2022年
14.3.4 提供製品
14.3.5 戦略的展望
14.4 Bayer AG
14.4.1 会社概要
14.4.2 会社概要
14.4.3 財務分析
14.4.3.1 純収入、2018-2022年
14.4.3.2 地域市場シェア、2022年
14.4.3.3 研究開発費、2018-2022年
14.4.4 提供製品
14.4.5 戦略的展望
14.5 Pfizer Inc.
14.5.1 会社概要
14.5.2 会社概要
14.5.3 財務分析
14.5.3.1 売上高、2018年～2022年
14.5.3.2 地域市場シェア、2022年
14.5.3.3 研究開発費、2018〜2022年
14.5.4 提供製品
14.5.5 戦略的展望
14.6 Bausch & Lomb Incorporated
14.6.1 会社概要
14.6.2 会社概要
14.6.3 財務分析
14.6.3.1 売上高、2018-2022年
14.6.3.2 研究開発費、2018-2022年
14.6.4 提供製品
14.6.5 戦略的展望
14.7 Santen Pharmaceutical Co., Ltd.
14.7.1 会社概要
14.7.2 会社概要
14.7.3 財務分析
14.7.3.1 売上高、2018-2022年
14.7.3.2 研究開発費（2018年～2022年
14.7.4 提供製品
14.7.5 戦略的展望
14.8 Johnson & Johnson Services, Inc.
14.8.1 会社概要
14.8.2 会社概要
14.8.3 財務分析
14.8.3.1 売上高、2018年～2022年
14.8.3.2 地域市場シェア、2022年
14.8.3.3 研究開発費、2018〜2022年
14.8.4 提供製品
14.8.5 戦略的展望
14.9 Regeneron Pharmaceuticals Inc.
14.9.1 会社概要
14.9.2 会社概要
14.9.3 財務分析
14.9.3.1 売上高、2018-2022年
14.9.3.2 研究開発費、2018年～2022年
14.9.4 提供製品
14.9.5 戦略的展望
14.10 AbbVie Inc.
14.10.1 会社概要
14.10.2 会社概要
14.10.3 財務分析
14.10.3.1 売上高、2018年～2022年
14.10.3.2 地域市場シェア、2022年
14.10.3.3 研究開発費、2018年〜2022年
14.10.4 提供製品
14.10.5 戦略的展望
14.11 F. Hoffmann-La Roche Ltd.
14.11.1 会社概要
14.11.2 会社概要
14.11.3 財務分析
14.11.3.1 売上高、2018年〜2022年
14.11.3.2 地域市場シェア、2022年
14.11.4 提供製品
14.11.5 戦略的展望
14.12 Teva Pharmaceutical Industries Ltd.
14.12.1 企業スナップショット
14.12.2 会社概要
14.12.3 財務分析
14.12.3.1 売上高、2018年～2022年
14.12.3.2 地域市場シェア、2022年
14.12.3.3 研究開発費、2018年～2022年
14.12.4 提供製品
14.12.5 戦略的展望
14.13 アペリス製薬
14.13.1 会社概要
14.13.2 会社概要
14.13.3 財務分析
14.13.3.1 売上高、2018年～2022年
14.13.3.2 研究開発費（2018年～2022年
14.13.4 提供製品
14.13.5 戦略的展望
14.14 Apellis Pharmaceuticals
14.14.1 会社概要
14.14.2 会社概要
14.14.3 財務分析
14.14.3.1 売上高、2018-2022年
14.14.3.2 研究開発費、2018-2022年
14.14.4 提供製品
14.14.5 戦略的展望
14.15 EyeBio
14.15.1 会社概要
14.15.2 会社概要
14.15.3 提供製品
14.15.4 戦略的展望
14.16 SpliceBio
14.16.1 会社概要
14.16.2 会社概要
14.16.3 提供製品
14.16.4 戦略的展望
14.17 Breye Therapeutics ApS
14.17.1 会社概要
14.17.2 会社概要
14.17.3 提供製品
14.17.4 戦略的展望

15 結論と提言
15.1Visiongainからの結びの言葉
15.2 市場プレイヤーへの提言

ページTOPに戻る

図表リスト

表の一覧
Table 1 Macular degeneration (AMD) and other retinal diseases drug market Snapshot, 2023 & 2033 (US$ billion, CAGR %)
Table 2 Macular degeneration (AMD) and other retinal diseases drug Contract Manufacturing Market Forecast by Region 2023-2033 (US$ Billion, AGR%, CAGR%): "V" Shaped Recovery
Table 3 Macular degeneration (AMD) and other retinal diseases drug Contract Manufacturing Market Forecast by Region 2023-2033 (US$ Billion, AGR%, CAGR%): "U" Shaped Recovery
Table 4 Macular degeneration (AMD) and other retinal diseases drug Contract Manufacturing Market Forecast by Region 2023-2033 (US$ Billion, AGR%, CAGR%): "W" Shaped Recovery
Table 5 Macular degeneration (AMD) and other retinal diseases drug Contract Manufacturing Market Forecast by Region 2023-2033 (US$ Billion, AGR%, CAGR%): "L" Shaped Recovery
Table 6 Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Disease Indication, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 7 AMD Segment Market Forecast by Region, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 8 Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by AMD Type, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 9 Diabetic Macular Edema Market Forecast by Region, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 10 Diabetic Retinopathy Segment Market Forecast by Region, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 11 Retinal Vein Occlusion Segment Market Forecast by Region, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 12 Others Segment Market Forecast by Region, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 13 Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Route of Administration, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 14 Intravitreal Route Segment Market Forecast by Region, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 15 Intravenous Route Segment Market Forecast by Region, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 16 Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Distribution Channel, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 17 Hospital Pharmacies Segment Market Forecast by Region, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 18 Retail Pharmacy Segment Market Forecast by Region, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 19 E-Commerce Pharmacy Segment Market Forecast by Region, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 20 Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Region 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 21 North America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Country, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 22 North America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Disease Indication, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 23 North America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by AMD Type, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 24 North America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Route of Administration, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 25 North America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Distribution Channel, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 26 U.S. Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Country, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 27 Canada Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Country, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 28 Europe Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Country, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 29 Europe Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Disease Indication, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 30 Europe Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by AMD Type, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 31 Europe Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Route of Administration, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 32 Europe Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Distribution Channel, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 33 Germany Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Country, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 34 France Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 35 UK Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 36 Italy Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 37 Spain Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 38 Netherlands Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 39 Switzerland Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 40 Rest of Europe Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 41 Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Country, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 42 Asia-Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Disease Indication, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 43 Asia-Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by AMD Type, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 44 Asia-Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Route of Administration, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 45 Asia-Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Distribution Channel, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 46 Japan Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 47 China Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 48 India Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 49 Australia Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 50 South Korea Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 51 South East Asia Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 52 Asia-Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 53 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Country, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 54 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Disease Indication, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 55 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by AMD Type, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 56 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Route of Administration, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 57 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Distribution Channel, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 58 Brazil Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 59 Mexico Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 60 Argentina Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 61 Rest of Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 62 MEA Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Country, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 63 MEA Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Disease Indication, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 64 MEA Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by AMD Type, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 65 MEA Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Route of Administration, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 66 MEA Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Distribution Channel, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 67 GCC Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 68 South Africa Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 69 Rest of MEA Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 70 Strategic Outlook
Table 71 Novartis AG: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 72 Novartis AG: Products Offered
Table 73 Novartis AG: Strategic Outlook
Table 74 Bayer AG: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 75 Bayer AG: Products Offered
Table 76 Bayer AG: Strategic Outlook
Table 77 Pfizer Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 78 Pfizer Inc.: Products Offered
Table 79 Pfizer Inc.: Strategic Outlook
Table 80 Bausch & Lomb Incorporated: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 81 Bausch & Lomb Incorporated: Products Offered
Table 82 Bausch & Lomb Incorporated: Strategic Outlook
Table 83 Santen Pharmaceutical Co., Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 84 Santen Pharmaceutical Co., Ltd.: Products Offered
Table 85 Santen Pharmaceutical Co., Ltd.: Strategic Outlook
Table 86 Johnson & Johnson Services, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 87 Johnson & Johnson Services, Inc.: Products Offered
Table 88 Johnson & Johnson Services, Inc.: Strategic Outlook
Table 89 Regeneron Pharmaceuticals Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 90 Regeneron Pharmaceuticals Inc.: Products Offered
Table 91 Regeneron Pharmaceuticals Inc.: Strategic Outlook
Table 92 AbbVie Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 93 AbbVie Inc.: Products Offered
Table 94 AbbVie Inc.: Strategic Outlook
Table 95 F. Hoffmann-La Roche Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 96 F. Hoffmann-La Roche Ltd.: Products Offered
Table 97 F. Hoffmann-La Roche Ltd.: Strategic Outlook
Table 98 Teva Pharmaceutical Industries Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 99 Teva Pharmaceutical Industries Ltd.: Products Offered
Table 100 Teva Pharmaceutical Industries Ltd.: Strategic Outlook
Table 101 Apellis Pharmaceuticals: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 102 Apellis Pharmaceuticals: Products Offered
Table 103 Apellis Pharmaceuticals: Strategic Outlook
Table 104 Alimera Sciences: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 105 Alimera Sciences: Products Offered
Table 106 Alimera Sciences: Strategic Outlook
Table 107 EyeBio: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 108 EyeBio: Products Offered
Table 109 EyeBio: Strategic Outlook
Table 110 SpliceBio: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 111 SpliceBio: Products Offered
Table 112 SpliceBio: Strategic Outlook
Table 113 Breye Therapeutics ApS: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 114 Breye Therapeutics ApS: Products Offered
Table 115 Breye Therapeutics ApS: Strategic Outlook

List of Figures
Figure 1 Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Segmentation
Figure 2 Macular degeneration (AMD) and other retinal diseases drug market by Disease Indication: Market Attractiveness Index
Figure 3 Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Route of Administration: Market Attractiveness Index
Figure 4 Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Distribution Channel: Market Attractiveness Index
Figure 5 Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Attractiveness Index by Region
Figure 6 Macular Degeneration (AMD) and Other Retinal Diseases Drug Market: Market Dynamics
Figure 7 Macular Degeneration (AMD) and Other Retinal Diseases Drug Market by Region, 2023-2033 (US$ Billion, AGR (%), CAGR (%)): “V” Shaped Recovery
Figure 8 Macular Degeneration (AMD) and Other Retinal Diseases Drug Market by region, 2023-2033 (US$ Billion, AGR (%), CAGR (%)): “U” Shaped Recovery
Figure 9 Macular Degeneration (AMD) and Other Retinal Diseases Drug Market by Region, 2023-2033 (US$ Billion, AGR (%), CAGR (%)): “W” Shaped Recovery
Figure 10 Macular Degeneration (AMD) and Other Retinal Diseases Drug Market by Region, 2023-2033 (US$ Billion, AGR (%), CAGR (%)): “L” Shaped Recovery
Figure 11 Macular Degeneration (AMD) and Other Retinal Diseases Drug Market: Porter’s Five Forces Analysis
Figure 12 Macular Degeneration (AMD) and Other Retinal Diseases Drug Market: PEST Analysis
Figure 13 Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Disease Indication: Market Attractiveness Index
Figure 14 Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Disease Indication, 2023-2033 (US$ Billion)
Figure 15 Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Share Forecast by Disease Indication, 2023, 2028, 2033 (%)
Figure 16 Prescription Drugs Market Forecast by Region, 2023 2033 (US$ Billion)
Figure 17 Prescription Drugs Market Share Forecast by Region, 2023 & 2033 (%)
Figure 18 Diabetic Macular Edema Market Forecast by Region, 2023-2033 (US$ Billion)
Figure 19 Diabetic Macular Edema Market Share Forecast by Region, 2023 & 2033 (%)
Figure 20 Diabetic Retinopathy Market Forecast by Region, 2023-2033 (US$ Billion)
Figure 21 Diabetic Retinopathy Market Share Forecast by Region, 2023 & 2033 (%)
Figure 22 Retinal Vein Occlusion Segment Market Forecast by Region, 2023-2033 (US$ Billion)
Figure 23 Retinal Vein Occlusion Segment Market Share Forecast by Region, 2023 & 2033 (%)
Figure 24 Others Market Forecast by Region, 2023-2033 (US$ Billion)
Figure 25 Others Market Share Forecast by Region, 2023 & 2033 (%)
Figure 26 Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Route of Administration: Market Attractiveness Index
Figure 27 Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Route of Administration, 2023-2033 (US$ Billion)
Figure 28 Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Share Forecast by Route of administration, 2023, 2028, 2033 (%)
Figure 29 Intravitreal Route Market Forecast by Region, 2023-2033 (US$ Billion)
Figure 30 Intravitreal Route Market Share Forecast by Region, 2023 & 2033 (%)
Figure 31 Intravenous Route Market Forecast by Region, 2023-2033 (US$ Billion)
Figure 32 Intravenous Route Market Share Forecast by Region, 2023 & 2033 (%)
Figure 33 Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Phase: Market Attractiveness Index
Figure 34 Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast By Distribution Channel, 2023-2033 (US$ Billion)
Figure 35 Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Share Forecast by Distribution Channel, 2023, 2028, 2033 (%)
Figure 36 Hospital Pharmacies Market Forecast by Region, 2023-2033 (US$ Billion)
Figure 37 Hospital Pharmacies Market Share Forecast by Region, 2023 & 2033 (%)
Figure 38 Retail Pharmacy Market Forecast by Region, 2023-2033 (US$ Billion)
Figure 39 Retail Pharmacy Market Share Forecast by Region, 2023 & 2033 (%)
Figure 40 E-Commerce Pharmacy Market Forecast by Region, 2023-2033 (US$ Billion)
Figure 41 E-Commerce Pharmacy Market Share Forecast by Region, 2023 & 2033 (%)
Figure 42 Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast By Brands, 2023-2033 (US$ Billion)
Figure 43 Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Share Forecast by Brands, 2023, 2028, 2033 (%)
Figure 44 Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Region 2023 & 2033 (Revenue, CAGR%)
Figure 45 Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Share Forecast by Region 2023, 2028, 2033 (%)
Figure 46 Macular Degeneration (AMD) and Other Retinal Diseases Drug Market by Region, 2023-2033 (US$ Billion, AGR (%), CAGR (%))
Figure 47 North America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Attractiveness Index
Figure 48 North America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market by region, 2023, 2028 & 2033 (US$ Billion)
Figure 49 North America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Country, 2023-2033 (US$ Billion)
Figure 50 North America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Share Forecast by Country, 2023 & 2033 (%)
Figure 51 North America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Disease Indication, 2023-2033 (US$ Billion)
Figure 52 North America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Share Forecast by Disease Indication, 2023 & 2033 (%)
Figure 53 North America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Route of Administration, 2023-2033 (US$ Billion)
Figure 54 North America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Share Forecast by Route of Administration, 2023 & 2033 (%)
Figure 55 North America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Distribution Channel, 2023-2033 (US$ Billion
Figure 56 North America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Share Forecast by Distribution Channel, 2023 & 2033 (%)
Figure 57 U.S. Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast, 2023-2033 (US$ Billion, AGR %)
Figure 58 Canada Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast, 2023-2033 (US$ Billion, AGR %)
Figure 59 Europe Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Attractiveness Index
Figure 60 Europe Macular Degeneration (AMD) and Other Retinal Diseases Drug Market by Region, 2023, 2028 & 2033 (US$ Billion)
Figure 61 Europe Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Country, 2023-2033 (US$ Billion)
Figure 62 Europe Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Share Forecast by Country, 2023 & 2033 (%)
Figure 63 Europe Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Disease Indication, 2023-2033 (US$ Billion)
Figure 64 Europe Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Share Forecast by Disease Indication, 2023 & 2033 (%)
Figure 65 Europe Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Route of Administration, 2023-2033 (US$ Billion)
Figure 66 Europe Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Share Forecast by Route of Administration, 2023 & 2033 (%)
Figure 67 Europe Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Distribution Channel, 2023-2033 (US$ Billion
Figure 68 Europe Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Share Forecast by Distribution Channel, 2023 & 2033 (%)
Figure 69 Germany Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast, 2023-2033 (US$ Billion, AGR %)
Figure 70 France Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast, 2023-2033 (US$ Billion, AGR %)
Figure 71 UK Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast, 2023-2033 (US$ Billion, AGR %)
Figure 72 Italy Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast, 2023-2033 (US$ Billion, AGR %)
Figure 73 Spain Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast, 2023-2033 (US$ Billion, AGR %)
Figure 74 Netherlands Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast, 2023-2033 (US$ Billion, AGR %)
Figure 75 Switzerland Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast, 2023-2033 (US$ Billion, AGR %)
Figure 76 Rest of Europe Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast, 2023-2033 (US$ Billion, AGR %)
Figure 77 Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Attractiveness Index
Figure 78 Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drug Market by Region, 2023, 2028 & 2033 (US$ Billion)
Figure 79 Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Country, 2023-2033 (US$ Billion)
Figure 80 Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Share Forecast by Country, 2023 & 2033 (%)
Figure 81 Asia-Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Disease Indication, 2023-2033 (US$ Billion)
Figure 82 Asia-Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Share Forecast by Disease Indication, 2023 & 2033 (%)
Figure 83 Asia-Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Route of Administration, 2023-2033 (US$ Billion)
Figure 84 Asia-Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Share Forecast by Route of Administration, 2023 & 2033 (%)
Figure 85 Asia-Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Distribution Channel, 2023-2033 (US$ Billion
Figure 86 Asia-Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Share Forecast by Distribution Channel, 2023 & 2033 (%)
Figure 87 Japan Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast, 2023-2033 (US$ Billion, AGR %)
Figure 88 China Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast, 2023-2033 (US$ Billion, AGR %)
Figure 89 India Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast, 2023-2033 (US$ Billion, AGR %)
Figure 90 Australia Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast, 2023-2033 (US$ Billion, AGR %)
Figure 91 South Korea Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast, 2023-2033 (US$ Billion, AGR %)
Figure 92 South East Asia Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast, 2023-2033 (US$ Billion, AGR %)
Figure 93 Rest of Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast, 2023-2033 (US$ Billion, AGR %)
Figure 94 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Attractiveness Index
Figure 95 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market by Region, 2023, 2028 & 2033 (US$ Billion)
Figure 96 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Country, 2023-2033 (US$ Billion)
Figure 97 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Share Forecast by Country, 2023 & 2033 (%)
Figure 98 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Disease Indication, 2023-2033 (US$ Billion)
Figure 99 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Share Forecast by Disease Indication, 2023 & 2033 (%)
Figure 100 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Route of Administration, 2023-2033 (US$ Billion)
Figure 101 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Share Forecast by Route of Administration, 2023 & 2033 (%)
Figure 102 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Distribution Channel, 2023-2033 (US$ Billion
Figure 103 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Share Forecast by Distribution Channel, 2023 & 2033 (%)
Figure 104 Brazil Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast, 2023-2033 (US$ Billion, AGR %)
Figure 105 Mexico Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast, 2023-2033 (US$ Billion, AGR %)
Figure 106 Argentina Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast, 2023-2033 (US$ Billion, AGR %)
Figure 107 Rest of Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast, 2023-2033 (US$ Billion, AGR %)
Figure 108 MEA Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Attractiveness Index
Figure 109 MEA Macular Degeneration (AMD) and Other Retinal Diseases Drug Market by Region, 2023, 2028 & 2033 (US$ Billion)
Figure 110 MEA Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Country, 2023-2033 (US$ Billion)
Figure 111 MEA Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Share Forecast by Country, 2023 & 2033 (%)
Figure 112 MEA Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Disease Indication, 2023-2033 (US$ Billion)
Figure 113 MEA Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Share Forecast by Disease Indication, 2023 & 2033 (%)
Figure 114 MEA Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Route of Administration, 2023-2033 (US$ Billion)
Figure 115 MEA Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Share Forecast by Route of Administration, 2023 & 2033 (%)
Figure 116 MEA Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Distribution Channel, 2023-2033 (US$ Billion
Figure 117 MEA Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Share Forecast by Distribution Channel, 2023 & 2033 (%)
Figure 118 GCC Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast, 2023-2033 (US$ Billion, AGR %)
Figure 119 South Africa Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast, 2023-2033 (US$ Billion, AGR %)
Figure 120 Rest of MEA Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast, 2023-2033 (US$ Billion, AGR %)
Figure 121 Macular Degeneration (AMD) and Other Retinal Diseases Drug Market: Company Share Analysis, 2023
Figure 122 Novartis AG: Net Revenue, 2018-2022 (US$ million, AGR%)
Figure 123 Novartis AG: Regional Market Shares, 2022
Figure 124 Novartis AG: R&D Expense, 2018-2022 (US$ million, AGR%)
Figure 125 Bayer AG: Net Revenue, 2018-2022 (US$ million, AGR%)
Figure 126 Bayer AG: Regional Market Shares, 2022
Figure 127 Bayer AG: R&D Expense, 2018-2022 (US$ million, AGR%)
Figure 128 Pfizer Inc.: Annual Revenue, 2018-2022 (US$ million, AGR%)
Figure 129 Pfizer Inc.: Regional Market Shares, 2022
Figure 130 Pfizer Inc.: R&D Expense, 2018-2022 (US$ million, AGR%)
Figure 131 Bausch & Lomb Incorporated: Annual Revenue, 2018-2022 (US$ million, AGR%)
Figure 132 Bausch & Lomb Incorporated: R&D Expense, 2018-2022 (US$ million, AGR%)
Figure 133 Santen Pharmaceutical Co., Ltd.: Annual Revenue, 2018-2022 (US$ million, AGR%)
Figure 134 Santen Pharmaceutical Co., Ltd.: R&D Expense, 2018-2022 (US$ million, AGR%)
Figure 135 Johnson & Johnson Services, Inc.: Annual Revenue, 2018-2022 (US$ million, AGR%)
Figure 136 Johnson & Johnson Services, Inc.: Regional Market Shares, 2022
Figure 137 Johnson & Johnson Services, Inc.: R&D Expense, 2018-2022 (US$ million, AGR%)
Figure 138 Regeneron Pharmaceuticals Inc.: Annual Revenue, 2018-2022 (US$ million, AGR%)
Figure 139 Regeneron Pharmaceuticals Inc: R&D Expense, 2018-2022 (US$ million, AGR%)
Figure 140 AbbVie Inc.: Annual Revenue, 2018-2022 (US$ million, AGR%)
Figure 141 AbbVie Inc.: Regional Market Shares, 2022
Figure 142 AbbVie Inc.: R&D Expense, 2018-2022 (US$ million, AGR%)
Figure 143 F. Hoffmann-La Roche Ltd.: Annual Revenue, 2018-2022 (US$ million, AGR%)
Figure 144 F. Hoffmann-La Roche Ltd.: Regional Market Shares, 2022
Figure 145 Teva Pharmaceutical Industries Ltd.: Annual Revenue, 2018-2022 (US$ million, AGR%)
Figure 146 Teva Pharmaceutical Industries Ltd: Regional Market Shares, 2022
Figure 147 Teva Pharmaceutical Industries Ltd.: R&D Expense, 2018-2022 (US$ million, AGR%)
Figure 148 Apellis Pharmaceuticals: Annual Revenue, 2018-2022 (US$ million, AGR%)
Figure 149 Apellis Pharmaceuticals: R&D Expense, 2018-2022 (US$ million, AGR%)
Figure 150 Alimera Sciences: Annual Revenue, 2018-2022 (US$ million, AGR%)
Figure 151 Alimera Sciences: R&D Expense, 2018-2022 (US$ million, AGR%)

ページTOPに戻る

Table of Contents
List of Tables/Graphs

Summary

Report Details

The Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Report 2023-2033: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Rise in Incidence of Retinal Disorders and Upsurge in Geriatric Population Driving Industry Growth
The growth of the market for Macular Degeneration (AMD) and Other Retinal Diseases is significantly driven by various important factors. A primary contributor is the increasing occurrence of retinal conditions, particularly macular degeneration. The prevalence of these ailments is on the upswing globally, attributed to factors such as the aging population, unhealthy lifestyles, and increased exposure to risk elements like smoking and extended screen usage. Macular degeneration, a primary cause of vision loss in older individuals, has gained notable attention in the field of ophthalmology, resulting in increased investments in research, development, and innovative treatment methods.

Furthermore, the rise in the elderly population significantly contributes to market growth. As people age, the likelihood of developing retinal conditions such as AMD rises. With a growing proportion of elderly individuals worldwide, there’s a heightened demand for effective treatments to manage these conditions and preserve vision. This demographic shift accentuates the need for advanced therapeutics and comprehensive management strategies, driving the market for drugs and treatments targeting AMD and other retinal diseases.

In summary, the combination of a growing occurrence of retinal disorders and an expanding elderly population underscores the substantial demand for advancements in the Macular Degeneration (AMD) and Other Retinal Diseases Market. This highlights the importance of ongoing research, innovation, and accessible treatments to meet the evolving healthcare requirements of aging populations.

Lack of Awareness Regarding AMD Likely to Challenge Market Growth
The market for treating Macular Degeneration (AMD) and Other Retinal Diseases is significantly impacted by a major challenge—insufficient awareness regarding AMD. This predicament stems from a limited comprehension and knowledge within both the general populace and healthcare professionals about AMD, a progressive eye ailment that can result in vision impairment or loss. The issue centres around the fact that numerous individuals, particularly those in vulnerable demographics, lack awareness about the risk factors, symptoms, and potential consequences associated with AMD.

This deficiency in awareness creates notable obstacles for early diagnosis and timely intervention, as affected individuals may fail to identify the indicators of AMD until it reaches an advanced stage, diminishing the effectiveness of treatment options. Moreover, healthcare providers may face difficulty in detecting AMD during its initial phases due to the absence of routine screenings and inadequate public education about the condition.

What Questions Should You Ask before Buying a Market Research Report?
• How is the macular degeneration (AMD) and other retinal diseases drugs market evolving?
• What is driving and restraining the macular degeneration (AMD) and other retinal diseases drugs market?
• How will each macular degeneration (AMD) and other retinal diseases drugs market segment grow over the forecast period and how much revenue will these submarkets account for in 2033?
• How will the market shares for each macular degeneration (AMD) and other retinal diseases drugs market submarket develop from 2023 to 2033?
• What will be the main driver for the overall market from 2023 to 2033?
• Will leading macular degeneration (AMD) and other retinal diseases drugs markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
• How will the market shares of the national markets change by 2033 and which geographical region will lead the market in 2033?
• Who are the leading players and what are their prospects over the forecast period?
• How will the industry evolve during the period between 2023 and 2033? What are the implications of macular degeneration (AMD) and other retinal diseases drugs projects taking place now and over the next 10 years?
• Is there a greater need for product commercialisation to further scale the macular degeneration (AMD) and other retinal diseases drugs market?
• Where is the macular degeneration (AMD) and other retinal diseases drugs market heading and how can you ensure you are at the forefront of the market?
• What are the best investment options for new product and service lines?
• What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market today, and over the next 10 years:
• Our 284-page report provides 115 tables, 151 charts/graphs exclusively to you.
• The report highlights key lucrative areas in the industry so you can target them – NOW.
• It contains in-depth analysis of global, regional and national sales and growth.
• It highlights for you the key successful trends, changes and revenue projections made by your competitors.

This report tells you TODAY how the Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.

Forecasts to 2033 and other analyses reveal commercial prospects
• In addition to revenue forecasting to 2033, our new study provides you with recent results, growth rates, and market shares.
• You will find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising drug development prices and recent developments.

This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, “V”, “L”, “W” and “U” are discussed in this report.

Disease Indication
• AMD
– Wet AMD
– Dry AMD
• Diabetic Macular Edema
• Diabetic Retinopathy
• Retinal Vein Occlusion
• Others

Route of Administration
• Parenteral
• Topical

Brands
• Lucentis
• Eylea
• Avastin
• Beovu
• Vabysmo
• Ozurdex
• Others

Distribution Channel
• Hospital Pharmacies
• Retail Pharmacy
• E-commerce Pharmacies

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 24 leading national markets:

North America
• U.S.
• Canada

Europe
• Germany
• UK
• France
• Italy
• Spain
• Netherlands
• Switzerland
• Rest of Europe

Asia Pacific
• China
• Japan
• India
• Australia
• South Korea
• Southeast Asia
• Rest of Asia Pacific

Latin America
• Brazil
• Mexico
• Argentina
• Rest of Latin America

MEA
• GCC Countries
• South Africa
• Rest of MEA

The report also includes profiles and for some of the leading companies in the Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market, 2023 to 2033, with a focus on this segment of these companies’ operations.

Leading companies and the potential for market growth
• AbbVie Inc.
• Alimera Sciences
• Apellis Pharmaceuticals
• Bausch & Lomb Incorporated
• Bayer AG
• Breye Therapeutics ApS
• EyeBio
• F. Hoffmann-La Roche Ltd.
• Johnson & Johnson Services, Inc.
• Novartis AG
• Pfizer Inc.
• Regeneron Pharmaceuticals Inc.
• Santen Pharmaceutical Co., Ltd.
• SpliceBio
• Teva Pharmaceutical Industries Ltd.

Overall world revenue for Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market, 2023 to 2033 in terms of value the market will surpass US$15.0 billion in 2023, our work calculates. We predict strong revenue growth through to 2033. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market, 2023 to 2033 report help you?
In summary, our 280+ page report provides you with the following knowledge:

• Revenue forecasts to 2033 for Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market, 2023 to 2033 Market, with forecasts for disease indication, route of administration, distribution channel, and brand each forecast at a global and regional level – discover the industry’s prospects, finding the most lucrative places for investments and revenues.

• Revenue forecasts to 2033 for five regional and 24 key national markets – See forecasts for the Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market, 2023 to 2033 market in North America, Europe, Asia-Pacific, Latin America and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.

• Prospects for established firms and those seeking to enter the market – including company profiles for 15 of the major companies involved in the Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market, 2023 to 2033.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

Information found nowhere else
With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain’s study is for everybody needing commercial analyses for the Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market, 2023 to 2033, market-leading companies. You will find data, trends and predictions.

ページTOPに戻る

Table of Contents

1 Report Overview
1.1 Objectives of the Study
1.2 Introduction to Macular Degeneration (AMD) and Other Retinal Diseases Drug Market
1.3 What This Report Delivers
1.4 Why You Should Read This Report
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report for?
1.7 Methodology
1.7.1 Market Definitions
1.7.2 Market Evaluation & Forecasting Methodology
1.7.3 Data Validation
1.7.3.1 Primary Research
1.7.3.2 Secondary Research
1.8 Frequently Asked Questions (FAQs)
1.9 Associated Visiongain Reports
1.10 About Visiongain

2 Executive Summary

3 Market Overview
3.1 Key Findings
3.2 Market Dynamics
3.2.1 Market Driving Factors
3.2.1.1 Rise in Incidence of Retinal Disorders
3.2.1.2 Upsurge in Geriatric Population
3.2.1.3 Rising Healthcare Expenditure by Various Governments
3.2.2 Market Restraining Factors
3.2.2.1 Lack of Awareness Regarding AMD
3.2.2.2 Side Effects of Drugs
3.2.2.3 High Cost Associated with Macular Degeneration and Other Retinal Diseases
3.2.3 Market Opportunities
3.2.3.1 Growing Demand for Cutting-edge Therapeutic Treatments for Retinal Disorders to Aid Market
3.2.3.2 Untapped Opportunities for the Dry AMD Treatment
3.2.3.3 Increasing Adoption of New Technologies for Treatment
3.3 COVID-19 Impact Analysis
3.4 Porter’s Five Forces Analysis
3.4.1 Bargaining Power of Suppliers
3.4.2 Bargaining Power of Buyers
3.4.3 Competitive Rivalry
3.4.4 Threat from Substitutes
3.4.5 Threat of New Entrants
3.5 PEST Analysis
3.5.1 Political
3.5.2 Economical
3.5.3 Social
3.5.4 Technological

4 Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Analysis by Disease Indication
4.1 Key Findings
4.2 Disease Indication Segment: Market Attractiveness Index
4.3 Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Size Estimation and Forecast by Disease Indication
4.4 AMD
4.4.1 Market Size by Region, 2023-2033 (US$ Billion)
4.4.2 Market Share by Region, 2023 & 2033 (%)
4.4.3 AMD in Macular Degeneration (AMD) and Other Retinal Diseases Drug Market
4.5 Diabetic Macular Edema
4.5.1 Market Size by Region, 2023-2033 (US$ Billion)
4.5.2 Market Share by Region, 2023 & 2033 (%)
4.6 Diabetic Retinopathy
4.6.1 Market Size by Region, 2023-2033 (US$ Billion)
4.6.2 Market Share by Region, 2023 & 2033 (%)
4.7 Retinal Vein Occlusion
4.7.1 Market Size by Region, 2023-2033 (US$ Billion)
4.7.2 Market Share by Region, 2023 & 2033 (%)
4.8 Others
4.8.1 Market Size by Region, 2023-2033 (US$ Billion)
4.8.2 Market Share by Region, 2023 & 2033 (%)

5 Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Analysis by Route of Administration
5.1 Key Findings
5.2 Route of Administration Segment: Market Attractiveness Index
5.3 Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Size Estimation and Forecast by Route of administration
5.4 Intravitreal Route
5.4.1 Market Size by Region, 2023-2033 (US$ Billion)
5.4.2 Market Share by Region, 2023 & 2033 (%)
5.5 Intravenous Route
5.5.1 Market Size by Region, 2023-2033 (US$ Billion)
5.5.2 Market Share by Region, 2023 & 2033 (%)

6 Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Analysis by Distribution Channel
6.1 Key Findings
6.2 Distribution Channel Segment: Market Attractiveness Index
6.3 Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Size Estimation and Forecast by Distribution Channel
6.4 Hospital Pharmacies
6.4.1 Market Size by Region, 2023-2033 (US$ Billion)
6.4.2 Market Share by Region, 2023 & 2033 (%)
6.5 Retail Pharmacy
6.5.1 Market Size by Region, 2023-2033 (US$ Billion)
6.5.2 Market Share by Region, 2023 & 2033 (%)
6.6 E-Commerce Pharmacy
6.6.1 Market Size by Region, 2023-2033 (US$ Billion)
6.6.2 Market Share by Region, 2023 & 2033 (%)

7 Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Analysis by Brands
7.1 Key Findings
7.2 Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Size Estimation and Forecast by Brands

8 Macular degeneration (AMD) and Other Retinal Diseases Drug Market Analysis by Region
8.1 Key Findings
8.3 Regional Market Size Estimation and Forecast

9 North America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Analysis
9.1 Key Findings
9.2 North America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Attractiveness Index
9.3 North America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market by Country, 2023, 2028 & 2033 (US$ Billion)
9.4 North America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Size Estimation and Forecast by Country
9.5 North America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Size Estimation and Forecast by Disease Indication
9.5.1 North America AMD in Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Disease Indication
9.6 North America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Size Estimation and Forecast by Route of Administration
9.7 North America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Size Estimation and Forecast by Distribution channel
9.8 U.S. Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Analysis
9.9 Canada Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Analysis

10 Europe Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Analysis
10.1 Key Findings
10.2 Europe Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Attractiveness Index
10.3 Europe Macular Degeneration (AMD) and Other Retinal Diseases Drug Market by Country, 2023, 2028 & 2033 (US$ Billion)
10.4 Europe Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Size Estimation and Forecast by Country
10.5 Europe Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Size Estimation and Forecast by Disease Indication
10.5.1 Europe AMD in Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Disease Indication
10.6 Europe Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Size Estimation and Forecast by Route of Administration
10.7 Europe Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Size Estimation and Forecast by Distribution channel
10.8 Germany Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Analysis
10.9 France Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Analysis
10.10 UK Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Analysis
10.11 Italy Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Analysis
10.12 Spain Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Analysis
10.13 Netherlands Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Analysis
10.14 Switzerland Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Analysis
10.15 Rest of Europe Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Analysis

11 Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Analysis
11.1 Key Findings
11.2 Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Attractiveness Index
11.3 Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drug Market by Country, 2023, 2028 & 2033 (US$ Billion)
11.4 Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Size Estimation and Forecast by Country
11.5 Asia-Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Size Estimation and Forecast by Disease Indication
11.5.1 Asia-Pacific AMD in Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Disease Indication
11.6 Asia-Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Size Estimation and Forecast by Route of Administration
11.7 Asia-Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Size Estimation and Forecast by Distribution channel
11.8 Japan Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Analysis
11.9 China Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Analysis
11.10 India Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Analysis
11.11 Australia Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Analysis
11.12 South Korea Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Analysis
11.13 South East Asia Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Analysis
11.14 Rest of Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Analysis

12 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Analysis
12.1 Key Findings
12.2 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Attractiveness Index
12.3 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market by Country, 2023, 2028 & 2033 (US$ Billion)
12.4 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Size Estimation and Forecast by Country
12.5 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Size Estimation and Forecast by Disease Indication
12.5.1 Latin America AMD in Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Disease Indication
12.6 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Size Estimation and Forecast by Route of Administration
12.7 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Size Estimation and Forecast by Distribution Channel
12.8 Brazil Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Analysis
12.9 Mexico Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Analysis
12.10 Argentina Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Analysis
12.11 Rest of Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Analysis

13 MEA Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Analysis
13.1 Key Findings
13.2 MEA Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Attractiveness Index
13.3 MEA Macular Degeneration (AMD) and Other Retinal Diseases Drug Market by Country, 2023, 2028 & 2033 (US$ Billion)
13.4 MEA Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Size Estimation and Forecast by Country
13.5 MEA Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Size Estimation and Forecast by Disease Indication
13.5.1 MEA AMD in Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Disease Indication
13.6 MEA Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Size Estimation and Forecast by Route of Administration
13.7 MEA Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Size Estimation and Forecast by Distribution channel
13.8 GCC Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Analysis
13.9 South Africa Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Analysis
13.10 Rest of MEA Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Analysis

14 Company Profiles
14.1 Competitive Landscape, 2023
14.2 Strategic Outlook
14.3 Novartis AG
14.3.1 Company Snapshot
14.3.2 Company Overview
14.3.3 Financial Analysis
14.3.3.1 Net Revenue, 2018-2022
14.3.3.2 Regional Market Shares, 2022
14.3.3.3 R&D Expense, 2018-2022
14.3.4 Product Offered
14.3.5 Strategic Outlook
14.4 Bayer AG
14.4.1 Company Snapshot
14.4.2 Company Overview
14.4.3 Financial Analysis
14.4.3.1 Net Revenue, 2018-2022
14.4.3.2 Regional Market Shares, 2022
14.4.3.3 R&D Expense, 2018-2022
14.4.4 Products Offered
14.4.5 Strategic Outlook
14.5 Pfizer Inc.
14.5.1 Company Snapshot
14.5.2 Company Overview
14.5.3 Financial Analysis
14.5.3.1 Revenue, 2018-2022
14.5.3.2 Regional Market Shares, 2022
14.5.3.3 R&D Expense, 2018-2022
14.5.4 Products Offered
14.5.5 Strategic Outlook
14.6 Bausch & Lomb Incorporated
14.6.1 Company Snapshot
14.6.2 Company Overview
14.6.3 Financial Analysis
14.6.3.1 Revenue, 2018-2022
14.6.3.2 R&D Expense, 2018-2022
14.6.4 Products Offered
14.6.5 Strategic Outlook
14.7 Santen Pharmaceutical Co., Ltd.
14.7.1 Company Snapshot
14.7.2 Company Overview
14.7.3 Financial Analysis
14.7.3.1 Revenue, 2018-2022
14.7.3.2 R&D Expense, 2018-2022
14.7.4 Products Offered
14.7.5 Strategic Outlook
14.8 Johnson & Johnson Services, Inc.
14.8.1 Company Snapshot
14.8.2 Company Overview
14.8.3 Financial Analysis
14.8.3.1 Revenue, 2018-2022
14.8.3.2 Regional Market Shares, 2022
14.8.3.3 R&D Expense, 2018-2022
14.8.4 Products Offered
14.8.5 Strategic Outlook
14.9 Regeneron Pharmaceuticals Inc.
14.9.1 Company Snapshot
14.9.2 Company Overview
14.9.3 Financial Analysis
14.9.3.1 Revenue, 2018-2022
14.9.3.2 R&D Expense, 2018-2022
14.9.4 Products Offered
14.9.5 Strategic Outlook
14.10 AbbVie Inc.
14.10.1 Company Snapshot
14.10.2 Company Overview
14.10.3 Financial Analysis
14.10.3.1 Revenue, 2018-2022
14.10.3.2 Regional Market Shares, 2022
14.10.3.3 R&D Expense, 2018-2022
14.10.4 Products Offered
14.10.5 Strategic Outlook
14.11 F. Hoffmann-La Roche Ltd.
14.11.1 Company Snapshot
14.11.2 Company Overview
14.11.3 Financial Analysis
14.11.3.1 Revenue, 2018-2022
14.11.3.2 Regional Market Shares, 2022
14.11.4 Products Offered
14.11.5 Strategic Outlook
14.12 Teva Pharmaceutical Industries Ltd.
14.12.1 Company Snapshot
14.12.2 Company Overview
14.12.3 Financial Analysis
14.12.3.1 Revenue, 2018-2022
14.12.3.2 Regional Market Shares, 2022
14.12.3.3 R&D Expense, 2018-2022
14.12.4 Products Offered
14.12.5 Strategic Outlook
14.13 Apellis Pharmaceuticals
14.13.1 Company Snapshot
14.13.2 Company Overview
14.13.3 Financial Analysis
14.13.3.1 Revenue, 2018-2022
14.13.3.2 R&D Expense, 2018-2022
14.13.4 Products Offered
14.13.5 Strategic Outlook
14.14 Alimera Sciences
14.14.1 Company Snapshot
14.14.2 Company Overview
14.14.3 Financial Analysis
14.14.3.1 Revenue, 2018-2022
14.14.3.2 R&D Expense, 2018-2022
14.14.4 Products Offered
14.14.5 Strategic Outlook
14.15 EyeBio
14.15.1 Company Snapshot
14.15.2 Company Overview
14.15.3 Products Offered
14.15.4 Strategic Outlook
14.16 SpliceBio
14.16.1 Company Snapshot
14.16.2 Company Overview
14.16.3 Products Offered
14.16.4 Strategic Outlook
14.17 Breye Therapeutics ApS
14.17.1 Company Snapshot
14.17.2 Company Overview
14.17.3 Products Offered
14.17.4 Strategic Outlook

15 Conclusion and Recommendations
15.1 Concluding Remarks from Visiongain
15.2 Recommendations for Market Players

ページTOPに戻る

List of Tables/Graphs

List of Tables
Table 1 Macular degeneration (AMD) and other retinal diseases drug market Snapshot, 2023 & 2033 (US$ billion, CAGR %)
Table 2 Macular degeneration (AMD) and other retinal diseases drug Contract Manufacturing Market Forecast by Region 2023-2033 (US$ Billion, AGR%, CAGR%): "V" Shaped Recovery
Table 3 Macular degeneration (AMD) and other retinal diseases drug Contract Manufacturing Market Forecast by Region 2023-2033 (US$ Billion, AGR%, CAGR%): "U" Shaped Recovery
Table 4 Macular degeneration (AMD) and other retinal diseases drug Contract Manufacturing Market Forecast by Region 2023-2033 (US$ Billion, AGR%, CAGR%): "W" Shaped Recovery
Table 5 Macular degeneration (AMD) and other retinal diseases drug Contract Manufacturing Market Forecast by Region 2023-2033 (US$ Billion, AGR%, CAGR%): "L" Shaped Recovery
Table 6 Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Disease Indication, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 7 AMD Segment Market Forecast by Region, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 8 Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by AMD Type, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 9 Diabetic Macular Edema Market Forecast by Region, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 10 Diabetic Retinopathy Segment Market Forecast by Region, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 11 Retinal Vein Occlusion Segment Market Forecast by Region, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 12 Others Segment Market Forecast by Region, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 13 Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Route of Administration, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 14 Intravitreal Route Segment Market Forecast by Region, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 15 Intravenous Route Segment Market Forecast by Region, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 16 Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Distribution Channel, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 17 Hospital Pharmacies Segment Market Forecast by Region, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 18 Retail Pharmacy Segment Market Forecast by Region, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 19 E-Commerce Pharmacy Segment Market Forecast by Region, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 20 Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Region 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 21 North America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Country, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 22 North America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Disease Indication, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 23 North America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by AMD Type, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 24 North America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Route of Administration, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 25 North America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Distribution Channel, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 26 U.S. Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Country, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 27 Canada Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Country, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 28 Europe Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Country, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 29 Europe Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Disease Indication, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 30 Europe Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by AMD Type, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 31 Europe Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Route of Administration, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 32 Europe Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Distribution Channel, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 33 Germany Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Country, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 34 France Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 35 UK Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 36 Italy Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 37 Spain Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 38 Netherlands Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 39 Switzerland Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 40 Rest of Europe Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 41 Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Country, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 42 Asia-Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Disease Indication, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 43 Asia-Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by AMD Type, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 44 Asia-Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Route of Administration, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 45 Asia-Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Distribution Channel, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 46 Japan Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 47 China Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 48 India Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 49 Australia Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 50 South Korea Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 51 South East Asia Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 52 Asia-Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 53 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Country, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 54 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Disease Indication, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 55 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by AMD Type, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 56 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Route of Administration, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 57 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Distribution Channel, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 58 Brazil Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 59 Mexico Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 60 Argentina Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 61 Rest of Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 62 MEA Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Country, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 63 MEA Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Disease Indication, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 64 MEA Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by AMD Type, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 65 MEA Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Route of Administration, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 66 MEA Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Distribution Channel, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 67 GCC Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 68 South Africa Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 69 Rest of MEA Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast, 2023-2033 (US$ Billion, AGR%, CAGR%)
Table 70 Strategic Outlook
Table 71 Novartis AG: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 72 Novartis AG: Products Offered
Table 73 Novartis AG: Strategic Outlook
Table 74 Bayer AG: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 75 Bayer AG: Products Offered
Table 76 Bayer AG: Strategic Outlook
Table 77 Pfizer Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 78 Pfizer Inc.: Products Offered
Table 79 Pfizer Inc.: Strategic Outlook
Table 80 Bausch & Lomb Incorporated: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 81 Bausch & Lomb Incorporated: Products Offered
Table 82 Bausch & Lomb Incorporated: Strategic Outlook
Table 83 Santen Pharmaceutical Co., Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 84 Santen Pharmaceutical Co., Ltd.: Products Offered
Table 85 Santen Pharmaceutical Co., Ltd.: Strategic Outlook
Table 86 Johnson & Johnson Services, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 87 Johnson & Johnson Services, Inc.: Products Offered
Table 88 Johnson & Johnson Services, Inc.: Strategic Outlook
Table 89 Regeneron Pharmaceuticals Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 90 Regeneron Pharmaceuticals Inc.: Products Offered
Table 91 Regeneron Pharmaceuticals Inc.: Strategic Outlook
Table 92 AbbVie Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 93 AbbVie Inc.: Products Offered
Table 94 AbbVie Inc.: Strategic Outlook
Table 95 F. Hoffmann-La Roche Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 96 F. Hoffmann-La Roche Ltd.: Products Offered
Table 97 F. Hoffmann-La Roche Ltd.: Strategic Outlook
Table 98 Teva Pharmaceutical Industries Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 99 Teva Pharmaceutical Industries Ltd.: Products Offered
Table 100 Teva Pharmaceutical Industries Ltd.: Strategic Outlook
Table 101 Apellis Pharmaceuticals: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 102 Apellis Pharmaceuticals: Products Offered
Table 103 Apellis Pharmaceuticals: Strategic Outlook
Table 104 Alimera Sciences: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 105 Alimera Sciences: Products Offered
Table 106 Alimera Sciences: Strategic Outlook
Table 107 EyeBio: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 108 EyeBio: Products Offered
Table 109 EyeBio: Strategic Outlook
Table 110 SpliceBio: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 111 SpliceBio: Products Offered
Table 112 SpliceBio: Strategic Outlook
Table 113 Breye Therapeutics ApS: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 114 Breye Therapeutics ApS: Products Offered
Table 115 Breye Therapeutics ApS: Strategic Outlook

List of Figures
Figure 1 Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Segmentation
Figure 2 Macular degeneration (AMD) and other retinal diseases drug market by Disease Indication: Market Attractiveness Index
Figure 3 Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Route of Administration: Market Attractiveness Index
Figure 4 Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Distribution Channel: Market Attractiveness Index
Figure 5 Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Attractiveness Index by Region
Figure 6 Macular Degeneration (AMD) and Other Retinal Diseases Drug Market: Market Dynamics
Figure 7 Macular Degeneration (AMD) and Other Retinal Diseases Drug Market by Region, 2023-2033 (US$ Billion, AGR (%), CAGR (%)): “V” Shaped Recovery
Figure 8 Macular Degeneration (AMD) and Other Retinal Diseases Drug Market by region, 2023-2033 (US$ Billion, AGR (%), CAGR (%)): “U” Shaped Recovery
Figure 9 Macular Degeneration (AMD) and Other Retinal Diseases Drug Market by Region, 2023-2033 (US$ Billion, AGR (%), CAGR (%)): “W” Shaped Recovery
Figure 10 Macular Degeneration (AMD) and Other Retinal Diseases Drug Market by Region, 2023-2033 (US$ Billion, AGR (%), CAGR (%)): “L” Shaped Recovery
Figure 11 Macular Degeneration (AMD) and Other Retinal Diseases Drug Market: Porter’s Five Forces Analysis
Figure 12 Macular Degeneration (AMD) and Other Retinal Diseases Drug Market: PEST Analysis
Figure 13 Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Disease Indication: Market Attractiveness Index
Figure 14 Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Disease Indication, 2023-2033 (US$ Billion)
Figure 15 Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Share Forecast by Disease Indication, 2023, 2028, 2033 (%)
Figure 16 Prescription Drugs Market Forecast by Region, 2023 2033 (US$ Billion)
Figure 17 Prescription Drugs Market Share Forecast by Region, 2023 & 2033 (%)
Figure 18 Diabetic Macular Edema Market Forecast by Region, 2023-2033 (US$ Billion)
Figure 19 Diabetic Macular Edema Market Share Forecast by Region, 2023 & 2033 (%)
Figure 20 Diabetic Retinopathy Market Forecast by Region, 2023-2033 (US$ Billion)
Figure 21 Diabetic Retinopathy Market Share Forecast by Region, 2023 & 2033 (%)
Figure 22 Retinal Vein Occlusion Segment Market Forecast by Region, 2023-2033 (US$ Billion)
Figure 23 Retinal Vein Occlusion Segment Market Share Forecast by Region, 2023 & 2033 (%)
Figure 24 Others Market Forecast by Region, 2023-2033 (US$ Billion)
Figure 25 Others Market Share Forecast by Region, 2023 & 2033 (%)
Figure 26 Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Route of Administration: Market Attractiveness Index
Figure 27 Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Route of Administration, 2023-2033 (US$ Billion)
Figure 28 Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Share Forecast by Route of administration, 2023, 2028, 2033 (%)
Figure 29 Intravitreal Route Market Forecast by Region, 2023-2033 (US$ Billion)
Figure 30 Intravitreal Route Market Share Forecast by Region, 2023 & 2033 (%)
Figure 31 Intravenous Route Market Forecast by Region, 2023-2033 (US$ Billion)
Figure 32 Intravenous Route Market Share Forecast by Region, 2023 & 2033 (%)
Figure 33 Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Phase: Market Attractiveness Index
Figure 34 Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast By Distribution Channel, 2023-2033 (US$ Billion)
Figure 35 Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Share Forecast by Distribution Channel, 2023, 2028, 2033 (%)
Figure 36 Hospital Pharmacies Market Forecast by Region, 2023-2033 (US$ Billion)
Figure 37 Hospital Pharmacies Market Share Forecast by Region, 2023 & 2033 (%)
Figure 38 Retail Pharmacy Market Forecast by Region, 2023-2033 (US$ Billion)
Figure 39 Retail Pharmacy Market Share Forecast by Region, 2023 & 2033 (%)
Figure 40 E-Commerce Pharmacy Market Forecast by Region, 2023-2033 (US$ Billion)
Figure 41 E-Commerce Pharmacy Market Share Forecast by Region, 2023 & 2033 (%)
Figure 42 Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast By Brands, 2023-2033 (US$ Billion)
Figure 43 Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Share Forecast by Brands, 2023, 2028, 2033 (%)
Figure 44 Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Region 2023 & 2033 (Revenue, CAGR%)
Figure 45 Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Share Forecast by Region 2023, 2028, 2033 (%)
Figure 46 Macular Degeneration (AMD) and Other Retinal Diseases Drug Market by Region, 2023-2033 (US$ Billion, AGR (%), CAGR (%))
Figure 47 North America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Attractiveness Index
Figure 48 North America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market by region, 2023, 2028 & 2033 (US$ Billion)
Figure 49 North America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Country, 2023-2033 (US$ Billion)
Figure 50 North America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Share Forecast by Country, 2023 & 2033 (%)
Figure 51 North America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Disease Indication, 2023-2033 (US$ Billion)
Figure 52 North America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Share Forecast by Disease Indication, 2023 & 2033 (%)
Figure 53 North America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Route of Administration, 2023-2033 (US$ Billion)
Figure 54 North America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Share Forecast by Route of Administration, 2023 & 2033 (%)
Figure 55 North America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Distribution Channel, 2023-2033 (US$ Billion
Figure 56 North America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Share Forecast by Distribution Channel, 2023 & 2033 (%)
Figure 57 U.S. Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast, 2023-2033 (US$ Billion, AGR %)
Figure 58 Canada Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast, 2023-2033 (US$ Billion, AGR %)
Figure 59 Europe Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Attractiveness Index
Figure 60 Europe Macular Degeneration (AMD) and Other Retinal Diseases Drug Market by Region, 2023, 2028 & 2033 (US$ Billion)
Figure 61 Europe Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Country, 2023-2033 (US$ Billion)
Figure 62 Europe Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Share Forecast by Country, 2023 & 2033 (%)
Figure 63 Europe Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Disease Indication, 2023-2033 (US$ Billion)
Figure 64 Europe Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Share Forecast by Disease Indication, 2023 & 2033 (%)
Figure 65 Europe Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Route of Administration, 2023-2033 (US$ Billion)
Figure 66 Europe Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Share Forecast by Route of Administration, 2023 & 2033 (%)
Figure 67 Europe Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Distribution Channel, 2023-2033 (US$ Billion
Figure 68 Europe Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Share Forecast by Distribution Channel, 2023 & 2033 (%)
Figure 69 Germany Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast, 2023-2033 (US$ Billion, AGR %)
Figure 70 France Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast, 2023-2033 (US$ Billion, AGR %)
Figure 71 UK Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast, 2023-2033 (US$ Billion, AGR %)
Figure 72 Italy Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast, 2023-2033 (US$ Billion, AGR %)
Figure 73 Spain Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast, 2023-2033 (US$ Billion, AGR %)
Figure 74 Netherlands Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast, 2023-2033 (US$ Billion, AGR %)
Figure 75 Switzerland Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast, 2023-2033 (US$ Billion, AGR %)
Figure 76 Rest of Europe Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast, 2023-2033 (US$ Billion, AGR %)
Figure 77 Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Attractiveness Index
Figure 78 Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drug Market by Region, 2023, 2028 & 2033 (US$ Billion)
Figure 79 Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Country, 2023-2033 (US$ Billion)
Figure 80 Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Share Forecast by Country, 2023 & 2033 (%)
Figure 81 Asia-Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Disease Indication, 2023-2033 (US$ Billion)
Figure 82 Asia-Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Share Forecast by Disease Indication, 2023 & 2033 (%)
Figure 83 Asia-Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Route of Administration, 2023-2033 (US$ Billion)
Figure 84 Asia-Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Share Forecast by Route of Administration, 2023 & 2033 (%)
Figure 85 Asia-Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Distribution Channel, 2023-2033 (US$ Billion
Figure 86 Asia-Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Share Forecast by Distribution Channel, 2023 & 2033 (%)
Figure 87 Japan Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast, 2023-2033 (US$ Billion, AGR %)
Figure 88 China Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast, 2023-2033 (US$ Billion, AGR %)
Figure 89 India Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast, 2023-2033 (US$ Billion, AGR %)
Figure 90 Australia Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast, 2023-2033 (US$ Billion, AGR %)
Figure 91 South Korea Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast, 2023-2033 (US$ Billion, AGR %)
Figure 92 South East Asia Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast, 2023-2033 (US$ Billion, AGR %)
Figure 93 Rest of Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast, 2023-2033 (US$ Billion, AGR %)
Figure 94 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Attractiveness Index
Figure 95 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market by Region, 2023, 2028 & 2033 (US$ Billion)
Figure 96 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Country, 2023-2033 (US$ Billion)
Figure 97 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Share Forecast by Country, 2023 & 2033 (%)
Figure 98 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Disease Indication, 2023-2033 (US$ Billion)
Figure 99 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Share Forecast by Disease Indication, 2023 & 2033 (%)
Figure 100 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Route of Administration, 2023-2033 (US$ Billion)
Figure 101 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Share Forecast by Route of Administration, 2023 & 2033 (%)
Figure 102 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Distribution Channel, 2023-2033 (US$ Billion
Figure 103 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Share Forecast by Distribution Channel, 2023 & 2033 (%)
Figure 104 Brazil Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast, 2023-2033 (US$ Billion, AGR %)
Figure 105 Mexico Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast, 2023-2033 (US$ Billion, AGR %)
Figure 106 Argentina Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast, 2023-2033 (US$ Billion, AGR %)
Figure 107 Rest of Latin America Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast, 2023-2033 (US$ Billion, AGR %)
Figure 108 MEA Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Attractiveness Index
Figure 109 MEA Macular Degeneration (AMD) and Other Retinal Diseases Drug Market by Region, 2023, 2028 & 2033 (US$ Billion)
Figure 110 MEA Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Country, 2023-2033 (US$ Billion)
Figure 111 MEA Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Share Forecast by Country, 2023 & 2033 (%)
Figure 112 MEA Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Disease Indication, 2023-2033 (US$ Billion)
Figure 113 MEA Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Share Forecast by Disease Indication, 2023 & 2033 (%)
Figure 114 MEA Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Route of Administration, 2023-2033 (US$ Billion)
Figure 115 MEA Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Share Forecast by Route of Administration, 2023 & 2033 (%)
Figure 116 MEA Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast by Distribution Channel, 2023-2033 (US$ Billion
Figure 117 MEA Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Share Forecast by Distribution Channel, 2023 & 2033 (%)
Figure 118 GCC Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast, 2023-2033 (US$ Billion, AGR %)
Figure 119 South Africa Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast, 2023-2033 (US$ Billion, AGR %)
Figure 120 Rest of MEA Macular Degeneration (AMD) and Other Retinal Diseases Drug Market Forecast, 2023-2033 (US$ Billion, AGR %)
Figure 121 Macular Degeneration (AMD) and Other Retinal Diseases Drug Market: Company Share Analysis, 2023
Figure 122 Novartis AG: Net Revenue, 2018-2022 (US$ million, AGR%)
Figure 123 Novartis AG: Regional Market Shares, 2022
Figure 124 Novartis AG: R&D Expense, 2018-2022 (US$ million, AGR%)
Figure 125 Bayer AG: Net Revenue, 2018-2022 (US$ million, AGR%)
Figure 126 Bayer AG: Regional Market Shares, 2022
Figure 127 Bayer AG: R&D Expense, 2018-2022 (US$ million, AGR%)
Figure 128 Pfizer Inc.: Annual Revenue, 2018-2022 (US$ million, AGR%)
Figure 129 Pfizer Inc.: Regional Market Shares, 2022
Figure 130 Pfizer Inc.: R&D Expense, 2018-2022 (US$ million, AGR%)
Figure 131 Bausch & Lomb Incorporated: Annual Revenue, 2018-2022 (US$ million, AGR%)
Figure 132 Bausch & Lomb Incorporated: R&D Expense, 2018-2022 (US$ million, AGR%)
Figure 133 Santen Pharmaceutical Co., Ltd.: Annual Revenue, 2018-2022 (US$ million, AGR%)
Figure 134 Santen Pharmaceutical Co., Ltd.: R&D Expense, 2018-2022 (US$ million, AGR%)
Figure 135 Johnson & Johnson Services, Inc.: Annual Revenue, 2018-2022 (US$ million, AGR%)
Figure 136 Johnson & Johnson Services, Inc.: Regional Market Shares, 2022
Figure 137 Johnson & Johnson Services, Inc.: R&D Expense, 2018-2022 (US$ million, AGR%)
Figure 138 Regeneron Pharmaceuticals Inc.: Annual Revenue, 2018-2022 (US$ million, AGR%)
Figure 139 Regeneron Pharmaceuticals Inc: R&D Expense, 2018-2022 (US$ million, AGR%)
Figure 140 AbbVie Inc.: Annual Revenue, 2018-2022 (US$ million, AGR%)
Figure 141 AbbVie Inc.: Regional Market Shares, 2022
Figure 142 AbbVie Inc.: R&D Expense, 2018-2022 (US$ million, AGR%)
Figure 143 F. Hoffmann-La Roche Ltd.: Annual Revenue, 2018-2022 (US$ million, AGR%)
Figure 144 F. Hoffmann-La Roche Ltd.: Regional Market Shares, 2022
Figure 145 Teva Pharmaceutical Industries Ltd.: Annual Revenue, 2018-2022 (US$ million, AGR%)
Figure 146 Teva Pharmaceutical Industries Ltd: Regional Market Shares, 2022
Figure 147 Teva Pharmaceutical Industries Ltd.: R&D Expense, 2018-2022 (US$ million, AGR%)
Figure 148 Apellis Pharmaceuticals: Annual Revenue, 2018-2022 (US$ million, AGR%)
Figure 149 Apellis Pharmaceuticals: R&D Expense, 2018-2022 (US$ million, AGR%)
Figure 150 Alimera Sciences: Annual Revenue, 2018-2022 (US$ million, AGR%)
Figure 151 Alimera Sciences: R&D Expense, 2018-2022 (US$ million, AGR%)

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野の最新刊レポート

本レポートと同分野の最新刊レポートはありません。

Visiongain 社の最新刊レポート

本レポートと同じKEY WORD（distribution channel）の最新刊レポート

よくあるご質問

Visiongain社はどのような調査会社ですか?

英国の調査会社ヴィジョンゲイン社（Visiongain）は、通信とエネルギーのほか、自動車や化学・医薬品、金属など、広範な市場を対象に調査を行っています。自動車市場については、市場全般に関する調査のほ... もっと見る

調査レポートの納品までの日数はどの程度ですか?

在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。

注文の手続きはどのようになっていますか?

1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。

お支払方法の方法はどのようになっていますか?

納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。

データリソース社はどのような会社ですか?

当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。

黄斑変性症（AMD）およびその他の網膜疾患治療薬市場レポート：2023-2033

サマリー

目次

図表リスト

Summary

Table of Contents

List of Tables/Graphs

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

本レポートと同分野の最新刊レポート

Visiongain 社の最新刊レポート

本レポートと同じKEY WORD（distribution channel）の最新刊レポート

よくあるご質問

Visiongain社はどのような調査会社ですか?

調査レポートの納品までの日数はどの程度ですか?

注文の手続きはどのようになっていますか?

お支払方法の方法はどのようになっていますか?

データリソース社はどのような会社ですか?